Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Advanced Gynaecologic Malignancies
NCT02025985Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of selinexor in ovarian carcinoma, endometrial carcinoma, cervical carcinoma, sponsored by Karyopharm Therapeutics Inc.. Started Apr 2014; status: completed.
02
Drugs
selinexor
03
Conditions
ovarian carcinomaendometrial carcinomacervical carcinoma
Beyond the preview
Go deeper on NCT02025985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025985.